SFRP1 and breast cancer: We initially used three breast cancer cell lines (MDA-MB-435S, MDA-MB-436 and MDA-MB-468) to assess the knockdown efficiency of our siSFRP1, which most effectively disrupted SFRP1 expression in MDA-MB-436 cells (Figure 5D).